Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Key Highlights
- ➤Evogene (EVGN) receives Nasdaq extension through March 29, 2027, to regain $1 minimum bid compliance
- ➤EVGN must close at least $1 for ten consecutive business days to regain compliance
- ➤Failure to regain compliance by March 29, 2027 could trigger Nasdaq delisting notification
- ➤Evogene may consider a reverse share split among options to cure the deficiency
- ➤Nasdaq letter has no immediate effect; EVGN continues trading on Nasdaq Capital Market
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance PR Newswire
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that on March 30, 2026 the Company was notified, based on the previous 30 consecutive business days, that it is not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share. Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until September 28, 2026, to regain compliance.
Get started
Create a free account to read the full story.